<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002293</url>
  </required_header>
  <id_info>
    <org_study_id>026B</org_study_id>
    <secondary_id>5</secondary_id>
    <nct_id>NCT00002293</nct_id>
  </id_info>
  <brief_title>A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes</brief_title>
  <official_title>Nystatin Pastille for the Prophylaxis of Oral Candidiasis in Patients With AIDS or AIDS Related Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the
      prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or
      IV, CDC classification)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Candidiasis, Oral</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nystatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Experimental drugs (IND drugs) which are targeted specifically against the AIDS virus
             or which stimulate the immune system.

          -  Systemic or oral antibiotics.

        Patients must have AIDS or AIDS-related syndromes (HIV infection:

          -  Group III or IV, CDC classification) and not have been treated for oral candidiasis
             during the past year.

          -  Patients can be entered into the study who have:

          -  Other oral lesions due to Kaposi's sarcoma, herpes zoster, and herpes simplex.

          -  A positive or negative oral culture for Candida.

          -  Must be able to follow instructions regarding the use of a pastille.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following are excluded:

          -  Oral lesions diagnostic of oral candidiasis or systemic candidiasis.

          -  Suspected or proven candidal esophagitis.

        Patients with the following are excluded:

          -  Oral lesions diagnostic of oral candidiasis or systemic candidiasis.

          -  Receiving any effective antifungal agent orally or intravenously within 72 hours of
             study entry.

          -  Not expected to survive for at least 6 months.

          -  Unable to voluntarily maintain a pastille in the buccal cavity for approximately 20
             minutes twice a day.

          -  Known hypersensitivity to nystatin.

          -  Suspected or proven candidal esophagitis.

        Prior Medication:

        Excluded within 72 hours of study entry:

          -  Any oral or intravenous antifungal agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Birmingham Veterans Administration Med Ctr / Univ of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol - Myers Squibb Co</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>085434000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <reference>
    <citation>MacPhail LA, Hilton JF, Dodd CL, Greenspan D. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 15;12(5):470-6.</citation>
    <PMID>8757423</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 1, 2007</last_update_submitted>
  <last_update_submitted_qc>October 1, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2007</last_update_posted>
  <keyword>Nystatin</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Candidiasis, Oral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nystatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

